Myriam Marussig


Myriam was appointed Chief Operating Officer of SparingVision in October 2017 to undertake the operational translation of the SPVN06 gene therapy candidate from Institut de la Vision into Development.

Prior to joining SparingVision, Myriam served as Senior Director of preclinical and early clinical development of Genticel, based in Toulouse (FR...


Roles at SparingVision

  • COO

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.